On June 16, 2005, Collini, Michael D.; Singhaus, Robert R.; Hu, Baihua; Jetter, James W.; Morris, Robert L.; Kaufman, David H.; Miller, Christopher P.; Ullrich, John W.; Unwalla, Rayomand J.; Wrobel, Jay E.; Quinet, Elaine; Nambi, Ponnal; Bernotas, Ronald C.; Elloso, Merle published a patent.Electric Literature of 142327-44-4 The title of the patent was Preparation of quinolines useful in treating LXR (liver X receptor)-mediated diseases. And the patent contained the following:
This invention provides quinolines of formula I (R1 = H or C1-C3 alkyl; X1 = a bond or an appropriate group to link R2 which is an optionally substituted heterocycle; X2 = a bond or CH2; R3 = optionally substituted Ph, naphthyl, or heterocycle; R4, R5, and R6 = H or F, R7 = H, C1-C4 alkyl, C1-C4 perfluoroalkyl, halogen, NO2, CN, optionally substituted phenyl) that are useful in the treatment or inhibition of LXR mediated diseases (no data). The LXR mediated diseases specifically claimed are, for example, atherosclerosis, Alzheimer’s disease, dementia, diabetes, multiple sclerosis, and thyroiditis. Pharmaceutical compositions containing the compounds of the invention and synthetic procedures for preparing them are also claimed. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Electric Literature of 142327-44-4
The Article related to quinoline preparation liver x receptor mediated disease treatment, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Electric Literature of 142327-44-4
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics